A raised prostate-specific antigen result needs a clear clinical plan, not a diagnosis made from one number. PSA can rise with benign prostate enlargement, inflammation, infection and prostate cancer. A result within the laboratory range does not completely exclude cancer either. The Wellness can review the report alongside symptoms, medicines, previous results and personal risk, then clarify whether a repeat test or specialist assessment is appropriate.
- PSA is a prostate marker, not a cancer diagnosis.
- NICE referral thresholds for people with possible prostate cancer symptoms are not universal screening cut-offs.
- A repeat test can be useful, but should not delay a referral when the clinical findings warrant one.
- MRI can help guide further assessment. A reassuring MRI does not remove every reason to consider a biopsy.
Arrange a doctor-led PSA results review
What does PSA measure?
Prostate-specific antigen, usually shortened to PSA, is a protein produced by the prostate. The test measures its concentration in blood. A report may use nanograms per millilitre, written as ng/mL, or micrograms per litre. These units are numerically equivalent, so a result of 3 ng/mL is the same concentration as 3 micrograms per litre.
PSA can be raised by different prostate conditions. Benign enlargement and prostatitis are among the possibilities, alongside prostate cancer. The number cannot identify the cause on its own. A clinician therefore interprets the result with the reason for testing, the person's age, urinary symptoms, medicines, examination findings and previous investigations.
That context matters after an executive health assessment. The blood report may have been taken while someone felt well, or it may sit alongside symptoms that have not yet been assessed. Those are different clinical situations. A careful review makes the distinction before deciding what the result should lead to.
What does a raised result mean for the next step?
The useful question is not simply whether the laboratory has flagged the result. It is whether the result, history and examination suggest a need for further assessment, and how quickly that assessment should happen.
NICE NG12 gives age-specific PSA thresholds for considering a suspected cancer pathway referral in people with possible symptoms of prostate cancer. Those symptoms include lower urinary tract symptoms, erectile dysfunction and visible blood in the urine. The thresholds are:
- Ages 40 to 49: more than 2.5 micrograms per litre.
- Ages 50 to 59: more than 3.5 micrograms per litre.
- Ages 60 to 69: more than 4.5 micrograms per litre.
- Ages 70 to 79: more than 6.5 micrograms per litre.
- Below 40 and above 79: clinical judgement rather than a fixed threshold.
NICE also says to take the person's preferences and other health conditions into account. These figures are referral thresholds in a defined symptomatic setting. They are not a diagnosis of cancer, a guarantee of safety below the threshold, or a universal rule for everyone having an executive screening test.
If a prostate feels malignant on digital rectal examination, NICE recommends a suspected cancer pathway referral. That recommendation is not dependent on first exceeding an age-specific PSA threshold. Symptoms and examination can change the plan even when the blood result looks reassuring.
The Wellness can help make the significance of a flagged result clear and identify when the next step should be a specialist referral rather than another routine screening appointment. Any proposed referral or investigation should have an agreed route, so the result does not remain an unexplained number in a report.
When is repeating the PSA useful?
A repeat can help when a temporary factor may have affected the first result. It is not an automatic requirement before every referral. Prostate Cancer UK explains that a doctor may suggest a further PSA test when another cause is thought to have raised the level, or may refer directly for specialist assessment when the overall findings warrant it.
A urine infection can raise PSA. Recent ejaculation, vigorous exercise and cycling can also affect the result. Recent prostate or bladder procedures, a prostate biopsy and a urinary catheter may change the timing of a useful test. A review should establish these details before the next sample is booked.
The NHS advises avoiding ejaculation, anal sex, vigorous exercise and cycling for 48 hours before a PSA test. Food and drink can usually be taken as normal for the PSA test itself. If the appointment includes other blood tests, the instructions for those tests may be different.
For a urine infection, the NHS describes waiting 4 to 6 weeks after the infection has cleared before testing. Prostate Cancer UK describes a wait of around six weeks. The treating clinician should set the timing in the individual situation, particularly after an infection, procedure or catheter. A person with concerning symptoms should receive assessment rather than simply wait for the next blood draw.
A good repeat-test plan records the date, the preparation advice, who will receive the result and what will happen if it remains raised. Agreeing those details turns a repeat into a follow-up pathway rather than a second isolated test.
Discuss a repeat PSA test and follow-up plan
Medicines can change the interpretation
Finasteride and dutasteride, medicines in the 5-alpha-reductase inhibitor group, can reduce the measured PSA. Prostate Cancer UK specifically advises telling the clinician about these medicines because they can affect how the result is interpreted.
This is relevant whether the medicine was prescribed for an enlarged prostate or for another reason. The person reading the blood result needs the medicine name and how long it has been taken, rather than relying on the laboratory range alone. Prescription and non-prescription treatments should be included in the review.
There is no need to stop a prescribed medicine to make a screening result easier to read. Changes to treatment should be agreed with the prescribing clinician. The immediate task is to make sure the result is interpreted with the correct medication history.
Earlier PSA measurements can also help. Their dates, the clinical circumstances and any change in treatment matter alongside the values. A sequence of numbers is useful context, but it should not replace assessment of a new symptom or examination finding.
What happens if specialist assessment is needed?
A referral is an assessment step, not a diagnosis. It allows a specialist to consider the PSA together with the history, examination, previous tests and the person's preferences. Further investigation should be based on that combined picture.
NICE NG131 recommends multiparametric MRI as the first-line investigation for suspected clinically localised prostate cancer. MRI can help identify areas that need closer assessment. NICE uses a five-point Likert score to describe the level of suspicion and recommends MRI-influenced biopsy when the score is 3 or more.
A low-suspicion MRI can support a discussion about avoiding biopsy, but it does not exclude all clinically significant cancer. NICE says a biopsy may be omitted with an MRI Likert score of 1 or 2 only after discussing the risks and benefits and reaching a shared decision. A person may still choose biopsy, and other risk factors can justify further investigation.
For people with raised PSA and a low-suspicion MRI who have not had a biopsy, NICE describes repeating PSA at 3 to 6 months. Strong clinical suspicion, for example a high PSA density, a concerning PSA change or a strong family history, can still lead to biopsy. This is why a normal-looking scan should come with a follow-up plan rather than an assumption that no further action will ever be needed.
NICE also says not to automatically offer a prostate biopsy on the basis of the PSA level alone. The balance is deliberate: identify clinically important disease while avoiding unnecessary investigation where possible. The individual's risks and preferences remain part of the decision.
The Wellness results review can clarify the reason for referral and the information that should accompany it. The scope and availability of any specialist imaging or procedure need to be confirmed separately. A blood-test consultation should not imply that an MRI, biopsy or specialist treatment is automatically included.
Should PSA be part of an executive health assessment?
PSA is best treated as an informed choice, rather than an automatic reassurance test. Testing can help identify prostate cancer before symptoms develop, including some cancers for which earlier detection matters. It can also lead to further tests for a raised result that is not cancer, or identify a slow-growing cancer that would never have caused harm.
Prostate Cancer UK describes both benefits and disadvantages and advises discussing what matters to the individual. Age, family history, Black ethnicity, symptoms, general health and previous testing can all shape that conversation. A person with a prostate who has symptoms needs an assessment of those symptoms, not simply a discussion about screening.
The current NHS PSA information also distinguishes symptom-led testing from routine testing and describes a specific exception for people found to have a faulty BRCA2 gene. National policy and individual eligibility can change. The safest practical step is a current discussion with a doctor about whether testing is appropriate for the person, rather than assuming that one policy statement covers every risk group.
Within an executive assessment, the value is the clinical follow-through: an appropriate decision to test, interpretation of the result and a named next step where needed. A reassuring result should not be presented as proof that prostate cancer is absent. A raised result should not be presented as proof that it is present.
Symptoms that should not wait for a screening follow-up
An inability to pass urine needs urgent medical help. Fever or feeling seriously unwell with urinary symptoms also requires prompt assessment. Visible blood in the urine, new or persistent urinary symptoms or a concerning examination finding should be assessed through an appropriate clinical route, even if the PSA result is within the laboratory range.
NICE NG12 includes urinary frequency, getting up at night to pass urine, hesitancy, urgency and retention among symptoms that can prompt prostate assessment. It also includes erectile dysfunction and visible blood in the urine. These symptoms have several possible causes. The purpose of assessment is to identify the cause and the right pathway, not to infer it from a screening marker.
If the clinician has already advised urgent referral, arranging another routine PSA test should not replace that advice. The Wellness can review an existing report, but an enquiry message is not an emergency service.
Review an existing PSA report with The Wellness
What a clear PSA results review should deliver
A useful review brings the original report and earlier measurements together with the reason for testing, symptoms, medicines, recent infection and relevant procedures. It should explain what is known, what the test cannot settle and what the next decision depends on.
The outcome may be a planned repeat, specialist assessment or an agreed monitoring approach. The plan should identify who is responsible for the next result and what change would prompt earlier contact. If a specialist has already taken over the investigation, that pathway should remain clear rather than being duplicated by unrelated screening.
The Wellness offers a discreet, doctor-led review in London for people who want their blood results connected to a practical next step. The consultation scope, appointment options and fees can be confirmed before booking. Where examination or specialist investigation is needed, the appropriate arrangements should be agreed rather than assumed.
Enquire about a discreet PSA results consultation
Frequently asked questions
Is a raised PSA a diagnosis of prostate cancer?
No. Benign enlargement, inflammation, infection and prostate cancer can all raise PSA. The result needs interpretation alongside symptoms, medicines, examination and previous tests. A clinician may recommend a repeat or specialist assessment depending on that combined picture.
What is a normal PSA level for my age?
There is no single number that guarantees the absence of prostate cancer. NICE NG12 gives referral thresholds for people with possible prostate cancer symptoms: more than 2.5 micrograms per litre at 40 to 49, 3.5 at 50 to 59, 4.5 at 60 to 69 and 6.5 at 70 to 79. Below 40 and above 79, it recommends clinical judgement. These are not universal screening cut-offs.
How should I prepare for a repeat PSA test?
The NHS advises avoiding ejaculation, anal sex, vigorous exercise and cycling for 48 hours before testing. Food and drink can usually be taken normally for PSA itself. After a urine infection, a clinician should agree the timing; NHS guidance describes waiting 4 to 6 weeks after it has cleared. Recent procedures or a catheter can also affect timing.
Does a reassuring MRI mean I cannot need a biopsy?
No. NICE allows consideration of omitting biopsy after a low-suspicion MRI only after discussing the risks and benefits and reaching a shared decision. Some clinically significant cancers can be missed by MRI. PSA density, PSA change, family history and the wider assessment can still support biopsy or further follow-up.
Can finasteride or dutasteride affect the result?
Yes. These medicines can lower the measured PSA and change its interpretation. The clinician needs the medicine name and treatment history. Do not stop or change prescribed treatment because of a screening result without advice from the prescribing clinician.
Can I have a PSA review if my screening result is within range?
Yes. A review can explain the limitations of the result and consider symptoms, personal risk and any previous tests. A result within range does not completely exclude cancer. New symptoms or an urgent referral recommendation should be assessed through the appropriate clinical route, not deferred until another routine screening test.
Sources
- NICE NG12: suspected cancer recognition and referral, prostate recommendations 1.6.1 to 1.6.3 and Table 2.
- NICE NG131: prostate cancer diagnosis and management, MRI, biopsy and follow-up recommendations.
- Prostate Cancer UK: the PSA blood test, preparation, results and informed choice.
- NHS: prostatitis and urgent assessment.
- NHS: PSA test, reasons for testing and preparation.
This article provides general information, not an individual diagnosis or treatment recommendation. Follow the advice of the clinician responsible for your care.